{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:12:14Z","timestamp":1793265134680,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ophtha.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T02:02:10Z","timestamp":1505959330000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Immunosuppression for the Uveitides"],"prefix":"10.1016","volume":"125","author":[{"given":"Douglas A.","family":"Jabs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2017.08.007_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of non-infectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaophthalmol.2016.3289","article-title":"Prevalence of the uveitides in the United States","volume":"134","author":"Jabs","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09286580802478724","article-title":"Epidemiology of uveitis","volume":"15","author":"Jabs","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding uveitis: the impact of research on visual outcomes","volume":"30","author":"de Smet","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2017.08.007_bib10","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/aos.12987","article-title":"Direct and indirect resource use, healthcare costs and workforce absence in patients with non-infectious intermediate, posterior, or panuveitis","volume":"94","author":"Thorne","year":"2016","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.08.007_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09273940490883671","article-title":"Treatment of ocular inflammation","volume":"12","author":"Jabs","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2017.08.007_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0161-6420(99)90122-7","article-title":"Pars planitis: clinical features and class II HLA associations","volume":"106","author":"Raja","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ajo.2007.08.023","article-title":"Pars planitis: a 20-year study of incidence, clinical features, and outcomes","volume":"144","author":"Donaldson","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajo.2008.06.004","article-title":"Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archophthalmol.2009.368","article-title":"Fundus autofluorescence imaging of the white dot syndromes","volume":"128","author":"Yeh","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/IAE.0b013e318286cc77","article-title":"Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging","volume":"33","author":"Spaide","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.08.007_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/09273948.2013.855797","article-title":"Fundus autofluorescence imaging in multifocal choroiditis: beyond the spots","volume":"22","author":"Kramer","year":"2013","journal-title":"Ocular Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2017.08.007_bib20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","article-title":"Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study","volume":"120","author":"Gregory","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Kacmaz","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0002-9394(02)01350-8","article-title":"Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease","volume":"133","author":"Oh","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2007.08.039","article-title":"Loss of visual field among patients with birdshot chorioretinopathy","volume":"145","author":"Thorne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/09273948.2010.506973","article-title":"Restoration of retinal architecture following systemic immunosuppression in birdshot chorioretinopathy","volume":"18","author":"Forooghian","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2017.08.007_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ajo.2013.04.040","article-title":"Risk of choroidal neovascularization among the uveitides","volume":"156","author":"Baxter","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib27","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting fluocinolone acetonide intravitreous implant vs. systemic anti-inflammatory therapy and visual outcomes at seven years among patients with intermediate, posterior, or panuveitis","volume":"317","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2017.08.007_bib28","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0161-6420(96)30417-X","article-title":"Prognosticators for visual outcome in sarcoid uveitis","volume":"103","author":"Dana","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(87)92870-4","article-title":"Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone","volume":"1","author":"Felson","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2017.08.007_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2017.08.007_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/09273948.2011.646382","article-title":"High-dose intravenous corticosteroids for ocular inflammatory diseases","volume":"20","author":"Charkoudian","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2017.08.007_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A\u00a0randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ophtha.2010.03.029","article-title":"A\u00a0cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States","volume":"118","author":"Nguyen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A\u00a0controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2017.08.007_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib39","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A\u00a0randomized clinical trial comparing methotrexate and mycophenolate mofetil for non-infectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2005.01.035","article-title":"Birdshot retinochoroidopathy: ocular complications and visual impairment","volume":"140","author":"Thorne","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib41","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.ophtha.2006.05.067","article-title":"Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity","volume":"113","author":"Thorne","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib42","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ajo.2005.04.052","article-title":"Vogt-Koyanagi-Harada disease: clinical outcomes","volume":"140","author":"Bykhovskaya","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib44","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib49","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib50","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ajo.2014.08.039","article-title":"Success with single agent immunosuppression for multifocal choroidopathies","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib51","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0161-6420(02)01097-7","article-title":"Successful treatment of serpiginous choroiditis with alkylating agents","volume":"109","author":"Akpek","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib52","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of ocular mucous membrane pemphigoid with immunosuppressive drugs","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib53","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A\u00a0prospective multicenter randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevi","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(01)00942-3","article-title":"Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation","volume":"109","author":"Goldstein","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2015.12.034","article-title":"Remission in intermediate uveitis: incidence and predictive factors","volume":"164","author":"Kempen","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.86.1.51","article-title":"An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood","volume":"86","author":"Edelsten","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","article-title":"Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis","volume":"151","author":"Kalinina Ayuso","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib58","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib59","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajo.2009.11.019","article-title":"The Multicenter Uveitis Steroid Treatment Trial: rationale, design, and baseline characteristics","volume":"149","author":"Kempen","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib60","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib61","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","article-title":"Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate, posterior and panuveitis: 54 month results of The Multicenter Uveitis Steroid Treatment Trial (MUST) and Follow-up Study","volume":"122","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib62","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.ophtha.2015.06.043","volume":"122","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib63","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib64","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib65","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ophtha.2015.07.036","article-title":"Outcome of treatment of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) Trial 2-year results","volume":"122","author":"Tomkins-Netzer","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib67","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib68","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2017.08.007_bib69","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ophtha.2010.03.023","article-title":"Chlorambucil and malignancy","volume":"117","author":"Birnbaum","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2014.08.024","article-title":"Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study","volume":"122","author":"Yates","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ophtha.2014.11.023","article-title":"Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions","volume":"122","author":"Khahachatryan","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib73","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib74","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib75","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2012.05.048","article-title":"Infliximab treatment of patients with birdshot retinochoroidopathy","volume":"120","author":"Artomsombudh","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib76","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib77","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib78","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib79","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib80","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for the prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2017.08.007_bib81","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib82","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib83","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis","volume":"42","author":"Tappeiner","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib84","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis","volume":"43","author":"Birolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.ophtha.2017.08.007_bib85","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.ophtha.2017.08.007_bib86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy. A multicenter study of 25 patients","volume":"69","author":"Calvo-Rio","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib87","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCE-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.08.007_bib88","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heligenhaus","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib89","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis","volume":"100","author":"Miserocchi","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of non-infectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.007_bib91","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000336324","article-title":"Interferon-\u03b1 therapy in non-infectious uveitis","volume":"51","author":"Deuter","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.007_bib93","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib94","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib95","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2017.08.007_bib96","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez Olivo","year":"2012","journal-title":"JAMA"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017315579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017315579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:06:05Z","timestamp":1758981965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017315579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0161642017315579"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.007","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression for the Uveitides","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}